Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives $26.50 Average Target Price from Brokerages

Integra LifeSciences Holdings Co. (NASDAQ:IART) has been assigned an average recommendation of “Reduce” from the nine analysts that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $26.50.

Several equities research analysts recently weighed in on the stock. JMP Securities reduced their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. Truist Financial lowered their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. Morgan Stanley raised their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Bank of America lowered their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Finally, BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Capital Research Global Investors increased its stake in shares of Integra LifeSciences by 37.7% in the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after purchasing an additional 1,621,655 shares in the last quarter. Cooke & Bieler LP lifted its holdings in shares of Integra LifeSciences by 12.4% in the 2nd quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock worth $102,406,000 after acquiring an additional 388,710 shares during the last quarter. Champlain Investment Partners LLC lifted its holdings in shares of Integra LifeSciences by 10.3% in the 1st quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock worth $95,289,000 after acquiring an additional 252,015 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Integra LifeSciences by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock worth $52,014,000 after buying an additional 12,766 shares during the period. Finally, D. E. Shaw & Co. Inc. increased its stake in shares of Integra LifeSciences by 64.6% in the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock worth $24,925,000 after buying an additional 335,557 shares during the period. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Performance

IART opened at $19.87 on Friday. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of 39.74, a price-to-earnings-growth ratio of 0.62 and a beta of 1.09. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42. The business has a 50 day moving average price of $19.03 and a two-hundred day moving average price of $25.51.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The company had revenue of $418.20 million during the quarter, compared to the consensus estimate of $413.07 million. During the same quarter in the prior year, the firm earned $0.71 EPS. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. Research analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.